World-leading life sciences cluster
Dense network of universities, corporates, start-ups and service providers
More than 160 biotech companies, among them a lot of start-ups, are developing therapeutics in Switzerland, which puts Switzerland in the same league as much larger countries, such as Germany and France. This strength can lead to spectacular success; for example, in 2017 Johnson & Johnson acquired Actelion, founded in 1997, for USD 30 billion. Switzerland also has great strength in the medtech sector, with the highest density of medtech companies in Europe.